Posted by admin on Aug 7th, 2022

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CEO Jeremy Bender sold 12,500 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $20.00, for a total transaction of $250,000.00. Following the sale, the chief executive officer now directly owns 1,246,192 shares in the company, valued at $24,923,840. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jeremy Bender also recently made the following trade(s):

Shares of DAWN opened at $23.64 on Friday. The stock’s 50-day moving average price is $15.75 and its two-hundred day moving average price is $12.76. Day One Biopharmaceuticals, Inc. has a 1 year low of $5.44 and a 1 year high of $28.70.

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09). On average, research analysts forecast that Day One Biopharmaceuticals, Inc. will post -2 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Canaan Partners XI LLC acquired a new position in Day One Biopharmaceuticals in the fourth quarter valued at about $162,832,000. Atlas Venture Life Science Advisors LLC lifted its holdings in shares of Day One Biopharmaceuticals by 9.3% during the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 8,968,305 shares of the company’s stock valued at $160,533,000 after purchasing an additional 766,667 shares in the last quarter. RA Capital Management L.P. grew its position in shares of Day One Biopharmaceuticals by 22.0% in the 1st quarter. RA Capital Management L.P. now owns 6,060,090 shares of the company’s stock valued at $60,116,000 after purchasing an additional 1,094,502 shares during the period. Deerfield Management Company L.P. Series C increased its stake in Day One Biopharmaceuticals by 28.7% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,202,533 shares of the company’s stock worth $37,113,000 after purchasing an additional 491,803 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in Day One Biopharmaceuticals by 54.6% during the 1st quarter. BlackRock Inc. now owns 1,162,916 shares of the company’s stock worth $11,537,000 after buying an additional 410,797 shares during the period. Institutional investors own 79.02% of the company’s stock.

A number of research analysts have issued reports on DAWN shares. Piper Sandler upped their target price on shares of Day One Biopharmaceuticals from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, June 20th. Wedbush raised their price objective on shares of Day One Biopharmaceuticals from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, June 13th.

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Zoe L. Dickson Sells 2,265 Shares of 3M (NYSE:MMM) Stock

Clifford Skelton Acquires 47,675 Shares of Conduent Incorporated (NASDAQ:CNDT) Stock